Demonstration Formulary
4 Central nervous system
PALLIATIVE CARE PHYSICIANS - Guidelines for the use of drugs in symptom control
04-03-03 Selective serotonin re-uptake inhibitors
| Citalopram |
|
Formulary
|
4 drops (8 mg) is equivalent in therapeutic effect to 10mg tablet Risk of QT prolongation |
 MHRA: New maximum daily dose restrictions (including in elderly patients), contraindications, and warnings UKMI Q&A: What issues should be considered regarding drug induced QT prolongation? |
|
| Vortioxetine |
|
Formulary
|
In line with NICE |
|
NICE TA367: Vortioxetine for treating major depressive episodes (Nov 2015) |
|
Links
- Administration of depot antipsychotic injections during COVID-19 in stable adult patients
- MHRA: New maximum daily dose restrictions (including in elderly patients), contraindications, and warnings
- MHRA: New maximum daily dose restrictions (including in elderly patients), contraindications, and warnings
NICE CG26: Post-traumatic stress disorder (PTSD)- NICE CG28: Depression in children and young people
- NICE CG31: Obsessive-compulsive disorder and body dysmorphic disorder: treatment
- NICE CG53: Chronic fatigue syndrome / Myalgic encephalomyelitis
- NICE CG90: Depression in adults (update)
- NICE CG91: Depression with a chronic physical health problem
- NICE TA367: Vortioxetine for treating major depressive episodes (Nov 2015)
UKMI Q&A: Can breastfeeding mothers take SSRI's?- UKMI Q&A: Epileptics - What is the most appropriate antidepressant to use?
- UKMI Q&A: Management of depression in breast feeding mothers - Are St.John’s Wort and other complementary therapies safe?
- UKMI Q&A: SSRIs with tramadol - risk of Serotonin Syndrome
- UKMI Q&A: What is serotonin syndrome and which medicines cause it?
- UKMI Q&A: What is the first choice antidepressant for patients with renal impairment?
- UKMI Q&A: What issues should be considered regarding drug induced QT prolongation?
- UKMI Q&A: What issues should be considered regarding drug induced QT prolongation?